Chemistry:Befetupitant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C29H29F6N3O2 |
| Molar mass | 565.560 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Befetupitant (Ro67-5930) is a drug developed by Hoffmann-La Roche which acts as a potent and selective antagonist for the NK1 receptor.[1] It was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development. Befetupitant has however continued to be researched for other possible applications such as treatment of corneal neovascularization.[2]
References
- ↑ "Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists". Bioorganic & Medicinal Chemistry Letters 16 (5): 1362–5. March 2006. doi:10.1016/j.bmcl.2005.11.047. PMID 16332435.
- ↑ "NK1 receptor antagonists as a new treatment for corneal neovascularization". Investigative Ophthalmology & Visual Science 55 (10): 6783–94. September 2014. doi:10.1167/iovs.14-14553. PMID 25228541.
 |  |
